Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer.
Bedard
Philippe L
PL
Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium.
Body
Jean-Jacques
JJ
Piccart-Gebhart
Martine J
MJ
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D009360:Neoplastic Cells, Circulating / Q000187:drug effects; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates